|Bid||0.00 x 900|
|Ask||0.00 x 1300|
|Day's Range||72.96 - 74.63|
|52 Week Range||60.89 - 85.97|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||18.80|
|Earnings Date||Jul 28, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||2.72 (3.62%)|
|Ex-Dividend Date||Jun 11, 2020|
|1y Target Est||80.25|
On Tuesday, Gilead Sciences announced that it would start to work on a new version of Remdesivir which would allow patients to inhale the medication. Yahoo Finance’s Anjalee Khemlani joins The Final Round to break down the latest news about the coronavirus.
The number of Americans with confirmed case of the coronavirus that causes COVID-19 climbed above 1.8 million on Tuesday, amid concerns that protests about the death of George Floyd last week, and people gathering in groups as lockdowns are lifted, will spark a fresh wave of infections.
Gilead's (GILD) shares decline on mixed results from a late-stage study on coronavirus drug.
In study results published last week, the Gilead drug seemed to get patients off a ventilator sooner than existing treatments. But an analyst notes the anomaly that patients on the drug for 5 days did better than those on it for 10 days.
Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19.
Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
Biotech company Gilead Sciences gained Food and Drug Administration emergency use authorization for its coronavirus treatment, remdesivir, in early May. Is Gilead stock a buy?
Remdesivir is the only drug so far that has been shown to help patients with COVID-19, but Gilead and other companies are looking for ways to make it work better. For critically ill patients, Roche and Eli Lilly and Co are testing drugs in combination with remdesivir. Gilead is also seeking to treat the virus earlier.
Between a big biotech with the leading COVID-19 therapy and a small biotech with a promising COVID-19 vaccine candidate, which stock wins?
A slice of data from the third clinical trial for Gilead Sciences Inc.’s remdesivir indicates that the experimental therapy is somewhat effective in treating COVID-19 patients but is not the silver bullet that had been hoped for.
India's government said on Tuesday it has approved Gilead Sciences Inc's antiviral drug remdesivir for emergency use for five doses in treating COVID-19 patients. Remdesivir, which is administered intravenously in hospital, is the first drug to show improvement in COVID-19 patients in formal clinical trials and is at the forefront of the battle against COVID-19, which has no approved treatment or vaccine. The drug was granted emergency use authorization by the U.S. Food and Drug Administration last month and has received approval by Japanese health regulators.
Shares in Gilead Sciences (GILD) traded down 3.4% on Monday after the company announced topline results from its Phase 3 SIMPLE trial in hospitalized patients with moderate Covid-19 pneumonia.This open-label study evaluated 5-day and 10-day courses of the investigational antiviral remdesivir plus standard of care, versus standard of care alone. The study demonstrated that patients in the 5-day remdesivir treatment group were 65% more likely to have clinical improvement at Day 11 compared with those in the standard of care group (OR 1.65 [95% CI 1.09-2.48]; p=0.017).The odds of improvement in clinical status with the 10-day treatment course of remdesivir versus standard of care trended towards- but did not reach- statistical significance (OR 1.31 [95% CI 0.88-1.95]; p=0.18).No new safety signals were identified with remdesivir across either treatment group. Gilead plans to submit the full data for publication in a peer-reviewed journal in the coming weeks.“These study results offer additional encouraging data for remdesivir, showing that if we can intervene earlier in the disease process with a 5-day treatment course, we can significantly improve clinical outcomes for these patients” said Francisco Marty of Harvard Medical School.Following the results, Needham analyst Alan Carr reiterated his Hold rating on GILD. “Our overall interpretation from both SIMPLE trials as well as the NIH ACTT-1 trial are that 5 and 10 day regimens are roughly equivalent and that the drug is of moderate benefit to COVID-19 patients” he explained.While the analyst acknowledges a central role for the drug in the treatment of Covid-19, he awaits clarity, on how, when, and for what price remdesivir will be distributed in the U.S. and ex-U.S. “We expect remdesivir to play a prominent role in the treatment of COVID-19 given the lack of other options” Carr says.Remdesivir is currently approved in Japan as a treatment for patients infected with SARS-CoV-2, the virus that causes Covid-19. Outside of Japan, remdesivir is an investigational, unapproved drug. The U.S. FDA granted remdesivir an Emergency Use Authorization for hospitalized patients with severe COVID-19, but this authorization is only temporary.Overall, the stock has a Hold analyst consensus based on 16 recent hold ratings, vs 8 buy ratings and 4 sell ratings. Meanwhile the average analyst price target stands at $79 for upside potential of 5%. Shares are currently trading up 16% year-to-date. (See GILD stock analysis on TipRanks).Related News: Immutep Surges In Pre-Market On Positive Efti Cancer Data Pfizer Loses 6% On Disappointing Ibrance Breast Cancer Outcome Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses More recent articles from Smarter Analyst: * Alphabet: Google Discovery Ads Represents Another Opportunity for Investors, Says 5-Star Analyst * Philips Gets FDA Emergency Use Nod For Monitors, Displays During Covid-19 Pandemic * National Instruments To Buy OptimalPlus In $365 Million Deal * 3 "Strong Buy" Penny Stocks That Could Go Boom
Asian stocks were set to come under pressure on Tuesday following a dip in Wall Street futures as U.S. President Donald Trump vowed to use force to end violent protests in American cities, souring a previously upbeat market mood. As Trump spoke in the Rose Garden of the White House on Monday, live television images showed police firing tear gas to dispel demonstrators in Lafayette Park, across the street. As Asian markets prepared to open, dozens of cities across the United States were under curfews with the National Guard deployed in 23 states and Washington, D.C.
Cruise ship stocks rallied on Monday, as optimism for COVID-19 vaccines and treatments rose. A flurry of encouraging coronavirus-related developments in recent days likely contributed to the gains in cruise ship stock prices. On Friday, Moderna (NASDAQ: MRNA) announced the commencement of its phase 2 study for its COVID-19 vaccine, mRNA-1273.
Jim Cramer discusses the stock market today including the protests in America, Gilead Sciences Covid-19 drug disappoints, and Coty's new CEO.
Early Monday, Gilead Sciences reported mixed results for its coronavirus treatment, remdesivir, in patients moderately ill with Covid-19. As a result, GILD stock dipped.
U.S. stocks posted gains on Monday as signs of U.S. economic recovery helped offset jitters over increasingly violent social unrest amid an ongoing pandemic and rising U.S.-China tensions. Market leaders Facebook Inc, Apple Inc and Amazon.com provided the biggest lift to the S&P 500 and the Nasdaq, while Boeing Co gave the Dow its biggest boost. "Certainly the pace of the stock market recovery can't continue at the pace it has been," said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago.
The global coronavirus pandemic converged on Monday with social unrest roiling the U.S., as hopes for relaxing lockdowns were undercut by raucous protests that prompted several big cities to impose curfews.
Protests and trade tensions can’t keep the stock market down as investors continue to focus on the reopening of the U.S. economy from the coronavirus-imposed shutdown.
Wall Street stocks posted modest gains on Monday as signs suggesting the U.S. economy may be on the road to recovery helped soothe jitters over increasingly violent social unrest and rising U.S.-China tensions. Market leaders Apple Inc, Amazon.com and Facebook Inc provided the biggest lift to the S&P 500 and the Nasdaq, while Boeing Co provided the blue-chip Dow with its biggest boost.
The number of global cases of the coronavirus that causes COVID-19 climbed above 6 million on Monday, after a weekend dominated by protests across the U.S. at the death of an unarmed black man at the hands of a white police officer in Minneapolis last week.
South Korea's Ministry of Food and Drug Safety approved a request by the country's health authorities to import Gilead Sciences Inc’s anti-viral drug remdesivir to treat COVID-19, the ministry said in a statement on Wednesday. The decision came after a government panel concluded last week that remdesivir showed positive results. The ministry said it will cooperate with the Korea Centers for Disease Control and Prevention (KCDC), other ministries and Gilead Sciences to swiftly import the drug.
Diodes Incorporated (Nasdaq: DIOD), today announced several enhanced corporate governance measures and compensation practices.